ICER, Aetion partnership aims to beef up cost-effectiveness analyses

ICER, Aetion partnership aims to beef up cost-effectiveness analyses

More reads

• This isn’t a ‘biotech. bubble,’ it’s ‘Philadelphia’s moment’ to become a center for gene therapy. (Philadelphia Enquirer) 
• New partnership tries to make up for missing drug data in cost-effectiveness analysis. (STAT)
• Repurposing leukemia drugs for lung cancer. (FierceBiotech)